Cedar Global Markets
Subscribe
SAVED POSTS
  • Login
No Result
View All Result
  • Home
  • Markets
  • Economy
  • Business
  • Energy
  • Technology
  • Global
    • Middle East
    • Europe
    • Asia-Pacific
    • Americas
    • Africa
  • Opinion
No Result
View All Result
  • Home
  • Markets
  • Economy
  • Business
  • Energy
  • Technology
  • Global
    • Middle East
    • Europe
    • Asia-Pacific
    • Americas
    • Africa
  • Opinion
Cedar Global Markets
US 2Y4.88%
US 10Y5.15%
US 30Y5.47%
2s10s+27bp
WTI$89.62
Brent$92.14
Fed funds3.75–4.00%
CPI3.7% YoY
Core CPI2.6% YoY
Unemployment4.1%
Cedar Global MarketsData via FRED® (St. Louis Fed). Not endorsed by the St. Louis Fed. Delayed / as published.

Summit Therapeutics Sinks 16% After the FDA Rejects Its Lung Cancer Drug Application

in Business, Americas
Reading Time: 4 mins read
Bar chart of Summit Therapeutics' daily closing share prices from Monday, Nov. 9, 2026, at $17.84 down to $14.15 on Friday, Nov. 13, then $11.82 at 2:20 p.m. Eastern time on Monday, Nov. 16, down 16.5%, below the stock's lowest close of the past year, $12.43 on Aug. 20, after the FDA rejected its lung cancer drug application.
byCedar Global Markets
November 16, 2026
0
Share on Facebook
Share on X

Summit Therapeutics shares fell about 16% on Monday after the U.S. Food and Drug Administration turned down its application for the lung cancer drug ivonescimab. The stock traded at $11.82 at 2:20 p.m. Eastern time, down $2.33, or 16.5%, from Friday’s close of $14.15.

Summit said on Sunday that the FDA had issued a complete response letter, meaning the application cannot be approved in its present form. The drug, given with chemotherapy, was meant for patients with advanced non-small cell lung cancer who had already been treated with EGFR-targeted drugs. In the HARMONi trial it significantly delayed the cancer’s progression, but the FDA said that without a statistically significant improvement in overall survival, the benefit did not support approval.

“We are disappointed for patients and their families awaiting additional treatment options in this setting,” Chairman and Co-Chief Executive Robert Duggan said. Summit said it will keep developing ivonescimab in other uses, including first-line lung cancer and colorectal cancer.

Monday’s price was below the stock’s lowest close of the past year, $12.43 on Aug. 20. The shares had already fallen 21% over the four trading days before the decision, from $17.84 on Nov. 9.

…

That’s the story. … Thank you for listening to Cedar Global Markets. We’re supported by our partners, and you can learn more about the partner featured on this page. We’ll see you next time.

TradingView partner
Tags: Homepage Latest BriefingMarket Movers

Related Posts

Grid of 100 squares representing $100 in State Street's SPDR S&P 500 ETF as of Nov. 13, 2026, with about 15 squares colored for chip stocks: Nvidia $6.04, Broadcom, Micron and AMD together $5.21, and 15 other chipmakers and chip-equipment makers $3.45, for about $14.70 in all.

Your 401(k) Is Riding on a Handful of Chip Stocks

by Cedar Global Markets
November 16, 2026
0

In a major S&P 500 index fund, about $14.70 of every $100 sits in chip stocks, $6 of...

Line chart of Tyson Foods' daily closing share price since Aug. 3, 2026, with a jump of 6.3% to $62.55 at 2:20 p.m. Eastern time on Monday, Nov. 16, from $58.82 at Friday's close, beside bars showing fiscal fourth-quarter adjusted earnings per share falling 47% to $0.61 from $1.15.

Tyson Foods Jumps 6% After Its Year-End Report and a Dividend Increase

by Cedar Global Markets
November 16, 2026
0

Tyson Foods rose 6.3% to $62.55 by 2:20 p.m. Eastern after reporting fourth-quarter adjusted earnings of 61 cents...

Bar showing UniCredit has secured just under half of Commerzbank's voting rights, above a timeline of approvals for its takeover: filed with EU regulators Oct. 9, European Central Bank approval in October, U.S. Federal Reserve approval in November, unconditional EU approval Nov. 16, and the last approval expected by the end of November.

EU Clears UniCredit’s Takeover of Commerzbank Without Conditions

by Cedar Global Markets
November 16, 2026
0

The European Commission found no competition concerns; UniCredit, which has secured just under half of Commerzbank's voting rights,...

Latest Briefing

Market Glance: Chip Stocks Drag Wall Street Lower Before Nvidia’s Report

November 16, 2026

Your 401(k) Is Riding on a Handful of Chip Stocks

November 16, 2026

Summit Therapeutics Sinks 16% After the FDA Rejects Its Lung Cancer Drug Application

November 16, 2026

Tyson Foods Jumps 6% After Its Year-End Report and a Dividend Increase

November 16, 2026
Next Post
Grid of 100 squares representing $100 in State Street's SPDR S&P 500 ETF as of Nov. 13, 2026, with about 15 squares colored for chip stocks: Nvidia $6.04, Broadcom, Micron and AMD together $5.21, and 15 other chipmakers and chip-equipment makers $3.45, for about $14.70 in all.

Your 401(k) Is Riding on a Handful of Chip Stocks

Cedar Global Markets

Categories
  • Africa
  • Americas
  • Asia-Pacific
  • Banking
  • Business
  • Commodities
  • Economy
  • Energy
  • Europe
  • Global
  • Industry
  • Market Glance
  • Markets
  • Middle East
  • Opinion
  • Policy
  • Technology
  • Trade
[mc4wp_form]

© 2026 Cedar Global Markets  ·  About Us  ·  Contact  ·  Advertise  ·  Partners  ·  Privacy  ·  Terms

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Markets
  • Economy
  • Business
  • Energy
  • Technology
  • Global
    • Middle East
    • Europe
    • Asia-Pacific
    • Americas
    • Africa
  • Opinion
SAVED POSTS

© 2026 Cedar Global Markets